Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Advances review located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://reginae783vez1.worldblogged.com/profile